Combining eftilagimod alpha1 and PD-1 mAbs for treating patients with metastatic melanoma demonstrated that eftilagimod alpha was well tolerated and showed encouraging antitumor activity. The gene discussed is PDCD1; the disease is metastatic melanoma.